No abstract

Background: Despite the usefulness of traditional Chinese medicine (TCM) in the treatment of lower deep vein thrombosis (DVT), there is no consensus on safety and efficacy. We aim to systematically evaluate the safety and efficacy of TCM combined with Rivaroxaban in the treatment of lower limb DVT. Methods: An online search of databases such as Cochrane Library, Embase, Pubmed, and Web of science, as well as CBM, China Science and Technology Journal Database, China Knowledge Network (CNKI) and Wanfang Data (from inception to July, 2021) was performed. All published clinical randomized controlled trials (RCTs) were screened manually, evaluated for quality and considered for meta-analysis using RevMan 5.3. Results: Nine RCTs with a total of 730 cases were included, 368 cases in the trial group were treated with TCM combined with Rivaroxaban, and 362 cases in the control group were treated with Rivaroxaban alone after surgery. Clinical efficiency was significantly higher in the test group [OR = 3.33, 95% CI (2.01, 5.53), P < .00001], the circumference of the affected limb was significantly lower in the thigh and calf, respectively [MD = −1.48, 95% CI (−1.88, −1.09), P < .00001], [MD = −0.54, 95% CI (−0.62, −0.46), P < .00001], pain scores were significantly lower [MD = −0.97, 95% CI (−1.58, −0.36), P = .002], coagulation index plasma fibrinogen (FIB) was significantly lower [MD = −0.85, 95% CI (−1.18, −0.52), P < .00001], coagulation function index D-2 aggregates were significantly reduced [MD = −0.69, 95% CI (−1.13, −0.24), P = .002], serum hypersensitive C-reactive protein (hs-CRP) measurements were significantly reduced [MD = −5.37, 95% CI (−9.20, −1.55), P = .006], complications measurement was significantly lower [OR = 0.60, 95% CI (0.27, 1.30), P = .20], activated partial thrombin time (ATPP) measurement was significantly lower [MD = 5.70, 95% CI (4.28, 7.12), P < .00001] and prothrombin time (PT) measurement was significantly lower [MD = 1.64, 95% CI (0.70, 2.57), P = .0006]. Conclusion: Based on the available evidence, TCM combined with Rivaroxaban for treating lower extremity DVT have better clinical efficacy and safety profile, reducing the risk of bleeding complications and adverse effects. Further improved studies are needed to support this inference.

No abstract

To provide reference for prevention and control of SARS-CoV-2 infection through analysis of related factors of patients diagnosed and suspected with COVID-19. Methods: Data of 40 confirmed cases and 24 suspected cases of COVID-19 admitted from January to February 2020 in the Second People's Hospital of Jingzhou City were collected, and the differences in indicators and related factors between the confirmed and suspected groups were compared. Results: There was no significant difference in patients age and APACHEⅡ score between the two groups (P> 0.05). Compared with the suspected group, WBC and Neut decreased in the diagnosed group, and the difference was statistically significant (p <0.05). PCT, Lymph, hs-CRP, ALT, IL-6, LDH, CK and other indicators including; gender, fever, dry cough, limb soreness, fatigue, underlying disease, were not statistically significant (p> 0.05). There was no significant difference in the factors such as single lung lobe lesions and multiple lobe lesions (P> 0.05). Conclusion: There is no significant difference between the common COVID-19 patients and the suspected patients in terms of population characteristics, clinical manifestations and most laboratory tests.